These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 33057907)

  • 1. Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2.
    Pavoni V; Gianesello L
    J Thromb Thrombolysis; 2021 May; 51(4):1111-1112. PubMed ID: 33057907
    [No Abstract]   [Full Text] [Related]  

  • 2. Severe acute myopathy following SARS-CoV-2 infection: a case report and review of recent literature.
    Islam B; Ahmed M; Islam Z; Begum SM
    Skelet Muscle; 2021 Apr; 11(1):10. PubMed ID: 33883014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High prevalence of antinuclear antibodies and lupus anticoagulant in patients hospitalized for SARS-CoV2 pneumonia.
    Gazzaruso C; Carlo Stella N; Mariani G; Nai C; Coppola A; Naldani D; Gallotti P
    Clin Rheumatol; 2020 Jul; 39(7):2095-2097. PubMed ID: 32462425
    [No Abstract]   [Full Text] [Related]  

  • 4. Association of anticoagulation use with SARS-CoV2 detection.
    Kavecansky J; Dusendang JR; Tavakoli J; Schmittdiel J; Ho G; Loyles J; Pai A
    Thromb Res; 2021 Feb; 198():99-102. PubMed ID: 33310348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dizziness in SARS-CoV2: A Red Flag to Clinicians.
    Bilgi K; Raghavendra S
    J Assoc Physicians India; 2020 Sep; 68(9):76. PubMed ID: 32798353
    [No Abstract]   [Full Text] [Related]  

  • 6. Post-COVID-19 arthritis: a case report and literature review.
    Gasparotto M; Framba V; Piovella C; Doria A; Iaccarino L
    Clin Rheumatol; 2021 Aug; 40(8):3357-3362. PubMed ID: 33587197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging Therapeutic Approaches to COVID-19.
    Singh IK; Kumari P; Mittal P; Kumar A; Singal B; Hasan GM; Aggarwal R; Kamal MA; Singh A; Hassan MI
    Curr Pharm Des; 2021 Oct; 27(31):3370-3388. PubMed ID: 33550964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV2 induced respiratory distress: Can cannabinoids be added to anti-viral therapies to reduce lung inflammation?
    Byrareddy SN; Mohan M
    Brain Behav Immun; 2020 Jul; 87():120-121. PubMed ID: 32360437
    [No Abstract]   [Full Text] [Related]  

  • 9. Editorial - Sofosbuvir/Velpatasvir as a combination with strong potential activity against SARS-CoV2 (COVID-19) infection: how to use direct-acting antivirals as broad-spectrum antiviral agents.
    Izzi A; Messina V; Rinaldi L; Maggi P
    Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5193-5194. PubMed ID: 32495848
    [No Abstract]   [Full Text] [Related]  

  • 10. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
    Stratton CW; Tang YW; Lu H
    J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Ophthalmological care of SARS-CoV-2 positive patients in intensive care units].
    Schwarz L; Lwowski C; Schmack I; Müller M; Adam E; Zacharowski K; Kohnen T
    Ophthalmologe; 2020 Jul; 117(7):602-608. PubMed ID: 32617666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral favipiravir for patients with delayed SARS-CoV-2 viral RNA clearance: a case series.
    Fu D; Cao R; Zhao L; Li W; Zhong W; Wen J
    Crit Care; 2020 Sep; 24(1):578. PubMed ID: 32977854
    [No Abstract]   [Full Text] [Related]  

  • 13. [First results of investigations of SARS-CoV‑2 RNA in human corneal tissue].
    Bayyoud T; Iftner T; Bartz-Schmidt KU; Rohrbach JM; Ueffing M; Schindler M; Thaler S
    Ophthalmologe; 2020 Jul; 117(7):615-617. PubMed ID: 32556553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On coming back, the scaring COVID-19 concern. Addressing indoor microclimates with innovative and straightforward solutions to prevent SARS-CoV2 spreading.
    Chirumbolo S; Tirelli U
    J Med Virol; 2024 Feb; 96(2):e29490. PubMed ID: 38377130
    [No Abstract]   [Full Text] [Related]  

  • 15. Initiation of Antiviral Treatment in SARS-CoV2: Modeling Viral Dynamics and Drug Properties.
    Rosenbloom DS; Zhao P; Sinha V
    CPT Pharmacometrics Syst Pharmacol; 2020 Sep; 9(9):481-483. PubMed ID: 32700405
    [No Abstract]   [Full Text] [Related]  

  • 16. A strategy targeting monocyte-macrophage differentiation to avoid pulmonary complications in SARS-Cov2 infection.
    Gómez-Rial J; Martinón-Torres F
    Clin Immunol; 2020 Jul; 216():108442. PubMed ID: 32335290
    [No Abstract]   [Full Text] [Related]  

  • 17. Ventilation support in SARS-CoV-2 pneumonia. Strategy and indication.
    Gordo F; Parro K; Mohamed M
    Rev Esp Quimioter; 2022 Apr; 35 Suppl 1(Suppl 1):50-53. PubMed ID: 35488827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV2 bilateral pneumonia: Chest X-ray evolution.
    Álvarez Méndez A; Matía Almudévar P; Álvarez Hernández S
    Med Intensiva (Engl Ed); 2022 Jul; 46(7):420-421. PubMed ID: 35527190
    [No Abstract]   [Full Text] [Related]  

  • 19. SARS-CoV2 Infection and Comorbidities, Role in Oncogenesis.
    Spirina LV; Masunova NV; Masunov VN; Makova VV; Dagbaeva YS; Kovaleva IV
    Asian Pac J Cancer Prev; 2022 Jul; 23(7):2191-2197. PubMed ID: 35901323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2-A Tough Opponent for the Immune System.
    Nasab MG; Saghazadeh A; Rezaei N
    Arch Med Res; 2020 Aug; 51(6):589-592. PubMed ID: 32532524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.